Erythropoietin Drugs Market Outlook
The global erythropoietin drugs market size was valued at a USD 6.87 Billion in 2022 and likely reach to USD 7.86 Billion by 2031, expanding at a CAGR of 1.5% during the forecast period, 2023–2031. The growth of the market is owing to the increasing cases of anemia and rising incidences of many sever disorders such as human immunodeficiency virus (HIV), and renal diseases globally.
Erythropoietin is a glycoprotein hormone that triggers erythropoiesis, or red blood cell formation in the bone marrow. Erythropoietin drug is primarily designed for the treatment of anaemia caused by dialysis and end-stage renal disease. Additionally, medications containing erythropoietin have been licensed for the treatment of chemotherapy-induced anemia.
Moreover, the high success rate of erythropoietin applications for chemotherapy-induced anemia, biopharmaceutical companies are now focusing on ART-induced anemia in HIV patients.
Furthermore, erythropoietin has various favorable cytoprotective properties such as anti-apoptotic, anti-ischemic, and regenerative effective on various tissues. In addition, it conducts its protective effects following trauma in severely ill patient through a specific receptor called EPOR-cR.
The COVID-19 pandemic had affected the healthcare industry as there was delay in the terms of production and disruption of supply chain of raw materials all over the world. Various industries, including several sub-domains of health care, have been forced to temporarily shut down their manufacturing process due to the pandemic outbreak.
However, the markets of certain medical services, notably erythropoietin, have been seen some positive effects due to increase in demand for treatment drugs and vaccines.
According to experts at the Max Planck Institute of Experimental Medicine in Göttingen, erythropoietin, as a medication for anemia, can be beneficial against the COVID-19 virus. Scientists are currently conducting several clinical experiments to explore the effects of treating COVID-19 with erythropoietin.
It is a hormone primarily produced by the kidneys, with hypoxia inducible factor-2 serving as its principal transcription element and inhibiting the red blood cell precursor apoptosis.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing demand for biologic and biosimilar drugs due to the rising cases of anemia is expected to boost the market.
- Expanding number of the geriatric population and increasing prevalence of chronic kidney diseases are fueling the growth of the market.
- Growing investments by governments into R&D programs for the development of the drugs are expected to propel the market growth in the coming years.
- High cost involved in drug development and lack of skilled- technician along with insufficient knowledge over the usage of drugs are main restraining factors that can hamper the market growth.
- Favorable regulatory terms such as early stage approval from regulatory bodies for erythropoietin drugs are projected to be great opportunities for pharmaceutical companies in the near future.
Scope of Erythropoietin Drugs Market Report
The report on the global erythropoietin drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Erythropoietin Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Products (Darbepoetin-alfa, Epoetin-alfa, Epoetin-beta, and Others), Drugs (Biosimilars, Biologics, and Others), and Applications (Neurology, Cancer, Hematology, and Renal Diseases)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Dr. Reddy’s Laboratories Ltd.; Biocon Ltd.; Amgen, Inc.; Celltrion, Inc.; Teva Pharmaceutical Industries Ltd.; F. Hoffmann-La Roche Ltd.; Intas Pharmaceuticals Ltd.; LG Life Sciences Ltd.; Sun Pharmaceutical Industries Ltd.; and Johnson & Johnson
|
Erythropoietin Drugs Market Segment Insights
Epoetin-alfa segment is expected to expand at a rapid pace
Based on products, the global erythropoietin drugs market is segmented into darbepoetin-alfa, epoetin-alfa, epoetin-beta, and others. The epoetin-alfa segment is expected to expand at a rapid pace during the forecast period owing to its large adoption by medical professional all over the world.
Another factor that is expected to fuel the segment growth is the high usage rate in improving condition of anemia in patients with chronic renal failure and cancer disease. In addition, the US Food and Drug Administration has approved epoetin-alfa as the first organic product for the treatment of anemia.
Biologics segment is projected to register a considerable growth in the market
On the basis of drugs, the market is segregated as biosimilar, biologics, and others. The biologics segment is projected to register a considerable growth in the market during the forecast period attributed the increasing presence of patient population and higher absorption of biologics.
Furthermore, biologics availability is comparatively less in the market, thus adoption of biologics is increasing. Moreover, the biologics segment has gained a large revenue share due to its vast usage in the treatment of chronic kidney disease.
On the other hand, the biosimilar segment is anticipated to register a high growth rate in the coming years. When compared to biologics, biosimilar are easy to produce and take less time to get approval. Furthermore, the recent introduction of erythropoietin biosimilar in the US is expected to shift in global erythropoietin medication development from biologics to biosimilar.
Cancer segment is projected to upsurge the market share significantly
In terms of applications, the global erythropoietin drugs market is categorized as neurology, cancer, hematology, and renal diseases. The cancer segment is projected to upsurge the market share significantly during the forecast period.
The growth of the segment is attributed to the rising incidences of cancer patient all around the world and the chemotherapy treatment procedure that decreases the red blood cells count among patients.
Erythropoietin Drugs Market Regional Outlook
North America is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period owing to the increasing cases of chronic diseases such as cancer, chronic kidney disease, and HIV in the region.
According to the Centers for Disease Control and Prevention (CDC), over 1.2 million people in the U.S. are suffering from HIV and the US government has implemented advantageous payment regulations for HIV treatment in order to meet unmet requirements.
Furthermore, as biologics patents are expiring, new companies have joined the market and are pursuing a variety of strategic tactics to secure a foothold.
On the other hand, the Asia Pacific market is estimated to expand at a considerable CAGR during the forecast period. Some factors such as exploding population, increasing cases of chronic disorders, and growing healthcare infrastructure are propelling the market growth in the region.
Segments
Products
- Darbepoetin-alfa
- Epoetin-alfa
- Epoetin-beta
- Others
Drugs
- Biosimilars
- Biologics
- Others
Applications
- Neurology
- Cancer
- Hematology
- Renal Diseases
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Some of the key players competing in the global erythropoietin drugs market are Dr. Reddy’s Laboratories Ltd.; Biocon Ltd.; Amgen, Inc.; Celltrion, Inc.; Teva Pharmaceutical Industries Ltd.; F. Hoffmann-La Roche Ltd.; Intas Pharmaceuticals Ltd.; LG Life Sciences Ltd.; Sun Pharmaceutical Industries Ltd.; and Johnson & Johnson.
These major players are implementing various marketing strategies such as capital investments, merger & acquisitions, and new product development to enhance their position in the market.
Due to the expiration of biologics' patents, this market is experiencing substantial expansion. It has invited a number of domestic and international companies to invest in the development of erythropoietin medications.
Furthermore, dealers & distributors are also elevating competition among them in order to gain larger share during the forecast period. Darbepoetin-alfa, an erythropoietin drug, is manufactured by Amgen, Inc. and sold under the name of Aranesp.
The better efficacy, cost-effectiveness, and lasting long- life are considered to be a viable therapy option for anemia caused by end-stage renal failure.
Request For Customization
Enquiry Before Buying
Speak With Analyst
